Oramed Pharmaceuticals Inc.
ORMP· Nasdaq
Filed Jul 17, 2013 · 10-Q · 47 days after period end · 0001178913-13-002087
| Metric | Q3 2013 | Q3 2012 | Q3 2011 |
|---|---|---|---|
| Net Income | -$1.26M | -$550.37K | $457.37K |
| EPS Diluted | $0.17 | $0.09 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
ended May 31, 2013 · filed Jul 17, 2013 · 47 d after period end